Diagnosis

Pemphigus vulgaris

A potentially life-threatening autoimmune, blistering disease affecting the skin and mucous membranes.

Etiology

Cause [bci]

Pathophysiology [p7h][bci]

  1. IgG autoantibodies directed against cell-adhesion molecules (desmogleins)

  2. This causes keratinocytes to fall apart (acabtholysis) --> bullous dermatosis

Less common types of pemphigus [k9p]

Complications [bci]

Epidemiology

Incidence per 100.000 [pyi][mce][y6b]

Epidemiology chart for Incidence

Symptoms & findings

Symptoms

Onychodystrophy, Paronychia, Subungual hematoma

Clinical findings

None listed.

Anamneses

None listed.

Localized findings

Rash
Radiates
CaputCollumThoraxAbdomenGenitalArmBackLower body
Distribution
AsymmetricLocalizedMultipleSymmetric
Lesion type
BullaErosion
Associated symptom
Pain
Palpation
Pain

Approach

Treatment

  1. First line treatment: [p7h][bci][0i5]

    • Prednisone 40 to 100 mg/day depending on severity

    • If control is not achieved: Methylprednisolone (1 g/day IV) or dexamethasone (300 mg/day IV) pulse therapy

    • Rituximab anti-CD 20 antibody

  2. Second line treatment: Steroid-sparing immunosuppressives (hypertension, diabetes mellitus, glaucoma, or osteoporosis)

    • Azathioprine 100-200 mg/day (1-3 mg/kg/day) orally, divided into two doses

    • Mycophenolate mofetil/sodium 2-3g/day, divided into two doses

  3. Third line treatment:

    • Intravenous human immunoglobulin (IVIG) 0.4g/kg/day for five days

    • Plasmapheresis/immunoadsorption

    • Cyclophosphamide orally (1-3 mg/kg/day)

    • Dapsone 50-200mg/day

    • Methotrexate 10 to 20mg/week

    • Cyclosporine 3-5mg/kg/day

    • Anti-TNF-α

  4. Antibiotics: if secondary infection, guided by culture of blood and skin samples

  5. Topical treatment: Always adjuvant to systemic treatment

    • Corticosteroid creams

    • Tacrolimus

    • Antibiotic creams

    • Antiseptic solutions (potassium permanganate)

Differential diagnoses

Aphthous stomatitis, Behcet's disease, Bullous pemphigoid, Dermatitis herpetiformis, Ecthyma, Eczema, Epidermolysis bullosa, Erysipelas, Erythema multiforme, Herpes simplex, Herpes zoster, IgA Pemphigus, Impetigo, Lichen planus, Paraneoplastic pemphigus, Pemphigus erythematosus, Pemphigus foliaceus, Stevens-Johnson syndrome, Systemic lupus erythematosus


References

[1] Ingold CJ, Sathe NC, Khan MAB. Pemphigus Vulgaris. [Updated 2024 Mar 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560860/

[2] Porro AM, Seque CA, Ferreira MCC, Enokihara MMSES. Pemphigus vulgaris. An Bras Dermatol. 2019 Jul 29;94(3):264-278.

[3] Hübner F, König IR, Holtsche MM, Zillikens D, Linder R, Schmidt E. Prevalence and age distribution of pemphigus and pemphigoid diseases among paediatric patients in Germany. J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2600-2605.

[4] Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. BMJ. 2008 Jul 9;337(7662):a180.

[5] Kridin K, Schmidt E. Epidemiology of Pemphigus. JID Innov. 2021 Feb 20;1(1):100004.

[6] Zhao L, Chen Y, Wang M. The Global Incidence Rate of Pemphigus Vulgaris: A Systematic Review and Meta-Analysis. Dermatology. 2023;239(4):514-522.

[7] http://emedicine.medscape.com/article/1064187; [Medscape]

[8] [Clinical Dermatology 4.th Edition by Weller, Hunter, Savin and Dahl]

Scroll to top